Thursday, May 4, 2006

lisofylline and exendin-4 by Yang at University of Virginia

Quote:
in this study we combined lisofylline to suppress autoimmunity and exendin-4 to enhance β-cell proliferation for treating autoimmune-mediated diabetes in the non-obese diabetic (NOD) mouse model. We found that this combined therapy effectively reversed new-onset diabetes within a week of therapy, and even maintained euglycemia up to 145 days after treatment withdrawal. 
Abstract: http://www.sciencedirect.com/science/article/pii/S0006291X06007066

1 comment:

  1. I don't know whether you caught the Feb 29, 2012 news release, but Islet Sciences, Inc. announced that the company entered into a Share Exchange Agreement to acquire DiaKine Therapeutics, Inc., whose most most clinically advanced drug is/was Lisofylline. The full press release can be viewed at http://prn.to/wi8mgd in case you're interested.

    ReplyDelete